MD Anderson Teams up with Industry Leader to Improve Targeted Therapies in Metastatic Disease (VIDEO)

University of Texas M. D. Anderson Cancer Center

Caption

The University of Texas MD Anderson Cancer Center announced an alliance with Boston-based Foundation Medicine and the opening of a randomized-controlled trial called IMPACT2 to determine whether targeted therapies selected from tumor biopsies results in longer progression-free survival in patients with advanced disease.

Credit

MD Anderson Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.